MedPath

Fludarabine

Generic Name
Fludarabine
Brand Names
Fludara
Drug Type
Small Molecule
Chemical Formula
C10H12FN5O4
CAS Number
21679-14-1
Unique Ingredient Identifier
P2K93U8740
Background

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication

For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions
B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1
Recruiting
Conditions
CBL Syndrome
JMML
Neurofibromatosis 1
JCML
Leukemia, Juvenile Myelomonocytic
Interventions
Drug: Trametinib
Drug: Azacitidine
Drug: Fludarabine
Drug: Cytarabine
First Posted Date
2023-05-09
Last Posted Date
2024-11-11
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
58
Registration Number
NCT05849662
Locations
🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

University of California San Francisco, San Francisco, California, United States

and more 1 locations

Allo HSCT Using RIC and PTCy for Hematological Diseases

Phase 2
Recruiting
Conditions
Plasma Cell Leukemia
Biphenotypic Acute Leukemia
Prolymphocytic Leukemia
Leukemia, Myeloid
Acute Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndromes
Acute Myelogenous Leukemia
Undifferentiated Leukemia
Myelodysplastic Syndrome With Excess Blasts-1
Interventions
Biological: Peripheral Blood Stem Cell Transplant
Drug: Allopurinol 300 MG
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Bone Marrow Cell Transplant
Radiation: Total Body Irradiation
Drug: Sirolimus Pill
Drug: Mycophenolate Mofetil
First Posted Date
2023-04-10
Last Posted Date
2024-05-07
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
56
Registration Number
NCT05805605
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

Phase 1
Recruiting
Conditions
Solid Tumor
Interventions
Biological: Neo-T
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
First Posted Date
2023-04-04
Last Posted Date
2023-04-04
Lead Sponsor
BGI, China
Target Recruit Count
21
Registration Number
NCT05798546
Locations
🇨🇳

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Not Applicable
Conditions
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Interventions
Drug: Obinutuzumab
Drug: Zanubrutinib
Drug: Lenalidomide
Drug: CD19/CD22 CAR-T
Drug: Azacitidine For Injection
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2023-04-04
Last Posted Date
2023-04-04
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
20
Registration Number
NCT05797948
Locations
🇨🇳

the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Phase 1
Active, not recruiting
Conditions
Chronic Lymphocytic Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma, B-Cell
Interventions
Biological: Anti-CD19 and anti-CD20 bicistronic CAR T- cells
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2023-04-04
Last Posted Date
2024-11-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
58
Registration Number
NCT05797233
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Phase 1
Not yet recruiting
Conditions
Refractory or Relapsed B Cell Lymphoma
Interventions
Drug: ThisCART19A
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Etoposide
First Posted Date
2023-03-20
Last Posted Date
2023-03-20
Lead Sponsor
Chongqing University Cancer Hospital
Target Recruit Count
12
Registration Number
NCT05776407
Locations
🇨🇳

Chongqing University Cancer Hospital, Chongqing, Chongqing, China

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Phase 2
Recruiting
Conditions
Multiple Myeloma
Smoldering Multiple Myeloma
Interventions
Drug: Ciltacabtagene Autoleucel
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
First Posted Date
2023-03-14
Last Posted Date
2024-07-18
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
20
Registration Number
NCT05767359
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Phase 2
Recruiting
Conditions
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Recurrent Acute Leukemia of Ambiguous Lineage
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Recurrent Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Lymphoblastic Leukemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Drug: Cytarabine
Drug: Calaspargase Pegol
Procedure: Echocardiography
Drug: Fludarabine Phosphate
Drug: Hydrocortisone Sodium Succinate
Procedure: Lumbar Puncture
Drug: Methotrexate
Drug: Revumenib
Procedure: Multigated Acquisition Scan
Drug: Prednisolone
Drug: Prednisone
Drug: Vincristine Sulfate
First Posted Date
2023-03-09
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
78
Registration Number
NCT05761171
Locations
🇺🇸

Kaiser Permanente Downey Medical Center, Downey, California, United States

🇺🇸

Renown Regional Medical Center, Reno, Nevada, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 62 locations

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

Phase 1
Recruiting
Conditions
Hematologic Diseases
Interventions
Biological: allogeneic γ9δ2 T Cells
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Zoredronic acid
First Posted Date
2023-03-06
Last Posted Date
2023-09-22
Lead Sponsor
Anhui Provincial Hospital
Target Recruit Count
10
Registration Number
NCT05755854
Locations
🇨🇳

Anhui Provincial Hospital, Hefei, Anhui, China

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2
Recruiting
Conditions
Hematologic Malignancy
Minimal Residual Disease
PTPN11 Gene Mutation
Monosomy 7
Chromosome Abnormality
Acute Leukemia
Remission
TP53
Intrachromosomal Amplification of Chromosome 21
Myelodysplasia
Interventions
Drug: Fludarabine
Drug: Rituximab
Drug: Busulfan
Drug: Melphalan
Drug: Levetiracetam
First Posted Date
2023-02-21
Last Posted Date
2024-10-21
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
150
Registration Number
NCT05735717
Locations
🇺🇸

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy